Technology | March 28, 2011

FDA Approves Two Cardiac Resynchronization Therapy-Pacemaker Systems

March 28, 2011 – The U.S. Food and Drug Administration (FDA) has approved two new cardiac resynchronization therapy-pacemaker (CRT-P) systems. The Consulta and Syncra CRT-P systems, from Medtronic, are the first to include OptiVol Fluid Status Monitoring.

The feature identifies patients at risk for worsening heart failure before symptoms develop.

Additionally, both Consulta and Syncra are the first CRT?Ps that include Leadless ECG Waveform. Together with the Medtronic CareLink Network device data monitoring system, the systems offer the possibility of remote follow?up in heart failure patients implanted with these devices. Shipments will begin immediately.

“Atrial arrhythmias are the number one cause of reduced cardiac resynchronization therapy; therefore, there is a real need for next?generation devices that can deliver lifesaving CRT in this patient population,” said Robert Canby, M.D., Texas Cardiac Arrhythmia and Seton Medical Center, Austin, Texas. “These new innovative technologies allow physicians to proactively manage their heart failure patients, and offer cutting?edge features that contribute to patient safety and physician ease?of?use.”

Both next?generation systems provide fully automatic capabilities and adaptive therapies that help to ensure CRT, even during atrial fibrillation, and enable physicians to monitor their heart failure patients in the office or remotely. Additionally, both systems include unique programming flexibility to avoid phrenic nerve stimulation, which helps prevent the need for more invasive surgical approaches.

While both systems include the same technology, they have differentiating features. Consulta includes the company’s OptiVol Fluid Status Monitoring, as well as Complete Capture Management, which monitors and adjusts to patient needs automatically and can positively impact device longevity and reduce in?office testing.

Cardiac resynchronization therapy (CRT), also known as bi?ventricular pacing, is a treatment for heart failure that uses an implantable device to improve the pumping efficiency of the heart. A cardiac resynchronization therapy?pacemaker is a stopwatch?sized device implanted in the upper chest to resynchronize the contractions of the ventricles. It sends tiny electrical pacing impulses to the heart muscle via leads (thin wires) to help the heart pump blood throughout the body more efficiently, reduce symptoms and help decrease mortality. CRT is intended to complement standard drug treatment, and dietary and lifestyle modifications.

For more information: www.medtronic.com

Related Content

INRatio, Alere, Abbott, I and R testing, INR testing
Feature | Point of Care Testing| December 07, 2016
December 7, 2016 — Abbott has filed a complaint to terminate its proposed acquisition of Alere based on the substanti
TCT 2016, TCT.16, main arena, late breaking trials, transcatheter cardiovascular therapeutics

There were several hot topics that came out of the 2016 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting Oct. 29 - Nov. 2, which made this month's top 20 list, including several videos. Number 4 on the list of content was the result of the EXCEL Trial key TCT late-breaker, which showed stenting is equal in outcomes to surgery for the first time, when using one of the latest generation drug-eluting stents. 

Feature | December 05, 2016
December 5, 2016 — Here is the list of the top 20 most popular pieces of content on the Diagnostic and Interventional
Boston Scientific, HeartLogic Heart Failure Diagnostic Service, MultiSENSE trial data, AHA Scientific Sessions 2016
News | Heart Failure| November 18, 2016
Boston Scientific recently announced results from the first clinical trial evaluating the performance of the HeartLogic...
atrial fibrillation, warfarin, dementia, Intermountain Medical Center Heart Institute, American Heart Association, AHA Scientific Sessions 2016
News | Atrial Fibrillation| November 15, 2016
Atrial fibrillation patients who use warfarin to lower risk of stroke are at higher risk of developing dementia than...
Medtronic, Claria MRI Quad CRT-D SureScan, FDA approval
Technology | Cardiac Resynchronization Therapy Devices (CRT)| November 15, 2016
Medtronic plc  has received U.S. Food and Drug Administration (FDA) approval for the Claria MRI Quad Cardiac...
catheter ablations, atrial fibrillation, stroke risk, Intermountain Medical Center Heart Institute study, AHA Scientific Sessions, American Heart Association
News | Ablation Systems| November 14, 2016
Atrial fibrillation patients with a prior history of stroke who undergo catheter ablation lower their long-term risk of...
Sponsored Content | Videos | Heart Valve Technology| November 14, 2016
William Abraham, M.D., FACC, discusses advances in heart failure device treatment technologies at the Transcatheter C
genetic testing, sudden cardiac death of teen, Mayo Clinic Proceedings
News | Genetic Testing| November 09, 2016
The recent, sudden death of a 13-year-old boy resulted in more than 20 relatives being incorrectly diagnosed as having...
transcatheter aortic valve replacement, pacemakers, implantation, post-TAVR implantation, worse outcomes, study
News | EP Lab| November 09, 2016
Patients who undergo minimally invasive heart valve replacement, known as transcatheter aortic valve replacement (TAVR...
Overlay Init